Search results
Results from the WOW.Com Content Network
The B-cell lymphomas are types of lymphoma affecting B cells. Lymphomas are "blood cancers" in the lymph nodes . They develop more frequently in older adults and in immunocompromised individuals.
The myeloid cell line normally produces granulocytes, erythrocytes, thrombocytes, macrophages and mast cells; the lymphoid cell line produces B, T, NK and plasma cells. Lymphomas, lymphocytic leukemias, and myeloma are from the lymphoid line, while acute and chronic myelogenous leukemia, myelodysplastic syndromes and myeloproliferative diseases ...
Atypical CLL/SLL-MBL Mantle cell lymphoma: The monoclonal B-cells in this aggressive lymphoma are CD5+ in most cases, CD10−, CD23−, CD43+, CD103−, complete Ig+, and express cyclin D1; these cells have translocations between chromosomes 11 and 14 in >95% of cases and in many cases overexpress the SOX11 transcription factor gene. [2]
Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes. [1] Symptoms may include feeling tired, pale skin color, fever, easy bleeding or bruising, enlarged lymph nodes, or bone pain. [1]
T-cell/histiocyte-rich large B-cell lymphoma most commonly afflicts middle-aged (i.e. 49–57 years old) individuals but has been diagnosed in persons aged 4 [6] to 92 years. [2] The disease has a male predominance ranging between 1.7:1 [ 3 ] to 3:1 [ 2 ] in different studies.
Diffuse large B-cell lymphoma is the most common of the large-cell lymphomas. MeSH now classifies the phrase "large-cell lymphoma" under "Diffuse large B cell lymphoma". [2] Many other B-cell lymphomas feature large cells: [citation needed] Angiocentric lymphoma; Burkitt's lymphoma; Follicular large-cell lymphoma; Immunoblastic lymphoma
The plasmablastic cells in B-cell lymphomas, including diffuse B-cell lymphomas, chronic lymphocytic leukemia/small lymphocytic lymphoma, and follicular lymphoma generally express CD20 and often express CD45 marker proteins. While PBL plasmablastic cells weakly express CD20 in 10% of cases, the strong expression of CD20 and the expression of ...
After this therapy, patients are infused with their own or the donor's hematopoietic stem cells. One study reported a 3-year survival rate of 36% and another reported a median progression-free survival time (i.e. time disease does not worsen) of 11.2 months with a median overall survival time that was not reached after 54 months of follow-up. [26]